Education
About Us
Working with TipRanks
Follow Us
Pfizer (PFE)
NYSE:PFE
Top Page
Pfizer
(NYSE:PFE)
68Neutral
Positive Factors
Business Development
Pfizer bought ADC leader Seagen for US$43bn, allowing Pfizer to develop ADCs, which boasts high efficacy and low adverse events.
Financial Performance
2024 Q4 results beat expectations with effective cost cuts and better-than-expected covid products sales.
Negative Factors
Patent Expiries
Investors remain concerned about the outlook for many of Pfizer's larger franchises due to upcoming patent expiries and competitive threats.
Regulatory Impact
Pfizer expects Part D redesign to disproportionately impact higher-priced drugs, including Ibrance, Xtandi, Vyndaqel, and Xeljanz.
Pfizer (PFE) vs. S&P 500 (SPY)
Market Cap
$137.76B
Dividend Yield6.96%
Average Volume (3M)53.78M
Price to Earnings (P/E)17.2
Beta (1Y)0.32
Revenue Growth8.77%
EPS Growth272.80%
CountryUS
Employees81,000
SectorHealthcare
Sector Strength79
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)1.41
Shares Outstanding5,671,454,600
10 Day Avg. Volume77,199,455
30 Day Avg. Volume53,775,849
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)N/A
Price to Sales (P/S)2.34
Price to Cash Flow (P/CF)5.50
P/FCF Ratio5.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.54Price Target Upside32.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Pfizer Business Overview & Revenue Model
Company DescriptionPfizer Inc. is a leading global pharmaceutical corporation headquartered in New York City. It engages in the discovery, development, manufacture, and sale of healthcare products, with a focus on medicines and vaccines. Pfizer operates across multiple therapeutic areas, including oncology, immunology, cardiology, and neurology, and is known for its innovative research and development efforts, contributing to the advancement of healthcare worldwide.
How the Company Makes MoneyPfizer generates revenue through the sale of its pharmaceutical products and vaccines. The company's revenue model primarily involves the development and commercialization of prescription medicines, which are sold directly to healthcare providers, governments, and distributors. Key revenue streams include sales from established biopharmaceutical products, innovative medicines, and vaccines. Pfizer also engages in strategic collaborations and partnerships to enhance its clinical development and expand its market reach, contributing significantly to its earnings. Additionally, the company benefits from intellectual property rights, which protect its products from generic competition, allowing it to maintain pricing power and profitability.
Pfizer Financial Statement Overview
Summary
Pfizer's financial performance shows resilience with improved profitability metrics in 2024. The income statement reflects better operational efficiency, though revenue growth is slower than previous years. The balance sheet indicates a strong equity position, but missing 2024 data raises caution. Cash flow analysis is hindered by a lack of recent data, necessitating transparency for stability.Income Statement
Pfizer has shown fluctuations in revenue with a significant decline from 2022 to 2023, followed by a recovery in 2024. Gross profit and net profit margins have improved in 2024, indicating better operational efficiency. The EBIT and EBITDA margins also show recovery, suggesting a return to profitability. However, the revenue growth rate from 2023 to 2024 is not as strong as previous years, indicating potential challenges in sustaining growth.75
Positive
Balance Sheet
The balance sheet reveals a strong equity position with positive stockholders' equity. However, the absence of total assets and total debt figures for 2024 raises concerns. Historically, Pfizer has managed a reasonable debt-to-equity ratio, but high liabilities in previous years suggest a need for careful leverage management. The equity ratio implies a stable financial foundation, although the missing metrics in 2024 warrant caution.65
Positive
Cash Flow
Pfizer's cash flow statement highlights a lack of data in 2024, raising concerns about cash generation capabilities. Previously, operating and free cash flows were positive, indicating strong cash flow management. The free cash flow to net income ratio has been healthy, but the missing 2024 data prevents a comprehensive assessment of current cash flow stability.60
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 63.63B | 58.50B | 100.33B | 81.29B | 41.91B | Gross Profit |
| 47.21B | 28.81B | 65.99B | 50.47B | 33.22B | EBIT |
| 14.94B | 3.36B | 40.03B | 24.83B | 10.63B | EBITDA |
| 18.13B | 9.56B | 41.03B | 30.79B | 13.17B | Net Income Common Stockholders |
| 8.03B | 2.12B | 31.37B | 21.98B | 7.02B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 20.48B | 12.69B | 22.73B | 31.07B | 12.22B | Total Assets |
| 213.40B | 226.50B | 197.21B | 181.48B | 154.23B | Total Debt |
| 63.65B | 70.84B | 34.87B | 37.00B | 38.27B | Net Debt |
| 62.61B | 67.99B | 34.45B | 35.05B | 36.49B | Total Liabilities |
| 124.90B | 137.21B | 101.29B | 104.01B | 90.76B | Stockholders Equity |
| 88.20B | 89.01B | 95.66B | 77.20B | 63.24B |
| Cash Flow | Free Cash Flow | |||
| 9.84B | 4.79B | 26.03B | 29.87B | 11.61B | Operating Cash Flow |
| 12.74B | 8.70B | 29.27B | 32.58B | 14.40B | Investing Cash Flow |
| 2.65B | -32.28B | -15.78B | -22.55B | -4.27B | Financing Cash Flow |
| -17.14B | 26.07B | -14.83B | -9.82B | -9.65B |
Pfizer Technical Analysis
Negative
22.97
Price Trends
25.89
Negative
25.77
Negative
26.85
Negative
Market Momentum
-0.28
Positive
33.44
Neutral
20.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Negative. The current price of 22.97 is below the 20-day moving average (MA) of 25.48, below the 50-day MA of 25.89, and below the 200-day MA of 26.85, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 33.44 is Neutral, neither overbought nor oversold. The STOCH value of 20.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PFE.
Pfizer Risk Analysis
Pfizer disclosed 26 risk factors in its most recent earnings report. Pfizer reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pfizer Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $218.22B | 12.82 | 40.81% | 3.66% | 6.85% | 4577.79% | |
71 Outperform | $356.70B | 84.36 | 61.94% | 3.12% | 3.71% | -12.14% | |
69 Neutral | $748.05B | 67.36 | 84.84% | 0.68% | 32.00% | 102.18% | |
69 Neutral | $385.14B | 27.60 | 20.06% | 3.10% | -4.51% | 3.69% | |
68 Neutral | $137.76B | 17.24 | 9.05% | 6.96% | 8.77% | 272.80% | |
60 Neutral | $117.65B | ― | -39.10% | 4.18% | 7.32% | -214.24% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% |
* Healthcare Sector Average
Performance Comparison
PFE
Pfizer
22.97
-2.04
-8.16%
BMY
Bristol Myers
55.30
6.59
13.53%
LLY
Eli Lilly & Co
738.21
-34.06
-4.41%
JNJ
Johnson & Johnson
153.24
6.36
4.33%
MRK
Merck & Company
81.47
-41.45
-33.72%
ABBV
AbbVie
186.96
23.13
14.12%
Pfizer Earnings Call Summary
Earnings Call Date: Feb 4, 2025 | % Change Since: -12.33% | Next Earnings Date: Apr 29, 2025
Earnings Call Sentiment Positive
Pfizer demonstrated strong financial performance and strategic progress in 2024, with significant achievements in market leadership and pipeline advancements. While there are challenges with specific products and external factors such as the IRA, the overall sentiment is positive due to the robust execution and strategic positioning for future growth.Highlights
Strong Financial Performance in 2024
Pfizer reported revenues of $63.6 billion for 2024, with operational revenue growth excluding COVID products at 12%, exceeding expectations of 9% to 11%.
Successful Integration of Seagen Business
Pfizer successfully integrated Seagen, creating a strong oncology segment, which is expected to enhance Pfizer's position in the industry.
Commercial Excellence and Market Leadership
Pfizer achieved the top position in the 2024 IQVIA U.S. Field Force Ranking report, claiming the #1 or #2 spot in 70% of the specialties it focuses on.
Pipeline Progress and Approvals
Pfizer reported more than a dozen approvals in 2024, with seven pivotal study starts and eight key Phase 3 readouts, indicating a robust pipeline.
Strong Performance of Key Products
Key products such as Padcev, Eliquis, and Nurtec showed significant growth, with Padcev becoming the #1 prescribed first-line treatment for metastatic urothelial cancer in the U.S.
Financial Discipline and Shareholder Returns
Pfizer expanded margins and returned $9.5 billion directly to shareholders through dividends, while deleveraging by $7.8 billion.
Lowlights
ABRYSVO and XELJANZ Declines
Pfizer noted declines in ABRYSVO and XELJANZ during the fourth quarter, impacting overall performance.
Challenges with COVID-19 Portfolio
While stabilizing, the COVID-19 portfolio has seen low vaccination rates and market stabilization at lower levels, posing challenges for future growth.
Impact of IRA Medicare Part D Redesign
The IRA is expected to be a net headwind, reducing Pfizer's revenue by approximately $1 billion in 2025, affecting growth by approximately 1.6% compared to 2024.
Company Guidance
In the fourth quarter of 2024 earnings call, Pfizer reported strong financial performance, meeting or exceeding strategic goals across various metrics. The company successfully integrated the Seagen business, enhancing its oncology capabilities, and reorganized its commercial operations into two divisions, U.S. and international, which improved its market presence. Pfizer achieved the top position in the 2024 IQVIA U.S. Field Force Ranking report and secured #1 or #2 spots in 70% of its targeted specialties. The company reported over a dozen approvals, seven pivotal study starts, and eight key Phase 3 readouts, reflecting robust pipeline progress. Financially, Pfizer ended 2024 with expanded margins, $11 billion invested in internal R&D, $7.8 billion in deleveraging, and $9.5 billion returned to shareholders through dividends. Looking ahead, Pfizer's 2025 priorities include enhancing R&D productivity, margin expansion, and continued focus on commercial excellence, with expectations for multiple key milestones in its R&D pipeline.Pfizer Corporate Events
Business Operations and StrategyFinancial Disclosures
Pfizer Projects Strong Financial Growth for 2025
Positive
Dec 17, 2024
Pfizer has announced its financial guidance for the full year 2025, projecting revenues between $61.0 and $64.0 billion, and adjusted diluted EPS between $2.80 and $3.00. The company expects operational growth in revenue and EPS, driven by cost savings and a strong product portfolio, despite challenges from the Inflation Reduction Act and generic competition.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.